Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
26 mai 2022 17h05 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus to Present at H.C. Wainwright Global Investment Conference
17 mai 2022 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
05 mai 2022 07h30 HE
|
Arbutus Biopharma Corporation
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Well positioned financially with a projected cash runway into the second quarter of 2024 ...
Holberton partners with Arbutus College in Vancouver, Canada, with the launch of a Computer Science and Front-end Web Development Diploma
27 avr. 2022 09h00 HE
|
Holberton
SAN FRANCISCO, April 27, 2022 (GLOBE NEWSWIRE) -- Holberton, an education company focused on making first-rate software-engineering education affordable and accessible worldwide, just announced the...
Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update
21 avr. 2022 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update
17 févr. 2022 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Announces 2022 Corporate Objectives and Provides Financial Update
24 janv. 2022 07h30 HE
|
Arbutus Biopharma Corporation
Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for...
Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
04 janv. 2022 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan
13 déc. 2021 07h30 HE
|
Arbutus Biopharma Corporation
Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong...
Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement
07 déc. 2021 07h30 HE
|
Arbutus Biopharma Corporation
Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks ...